FI930984A - Specifika bindningsaemne - Google Patents

Specifika bindningsaemne Download PDF

Info

Publication number
FI930984A
FI930984A FI930984A FI930984A FI930984A FI 930984 A FI930984 A FI 930984A FI 930984 A FI930984 A FI 930984A FI 930984 A FI930984 A FI 930984A FI 930984 A FI930984 A FI 930984A
Authority
FI
Finland
Prior art keywords
human antibody
reshaped
bindning
seed
hmfg1
Prior art date
Application number
FI930984A
Other languages
English (en)
Other versions
FI113873B (fi
FI930984A0 (fi
Inventor
Martine Elisa Verhoeyen
Original Assignee
Unilever Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Nv filed Critical Unilever Nv
Publication of FI930984A publication Critical patent/FI930984A/fi
Publication of FI930984A0 publication Critical patent/FI930984A0/fi
Application granted granted Critical
Publication of FI113873B publication Critical patent/FI113873B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI930984A 1990-09-07 1993-03-05 Menetelmä valmistaa muotoiltua ihmisen vasta-ainetta tai muotoiltua ihmisen vasta-ainefragmenttia, DNA-sekvenssejä, plasmidi ja pysyvä isäntäsolulinja FI113873B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909019553A GB9019553D0 (en) 1990-09-07 1990-09-07 Specific binding agents
GB9019553 1990-09-07
PCT/GB1991/001511 WO1992004380A1 (en) 1990-09-07 1991-09-05 Specific binding agents
GB9101511 1991-09-05

Publications (3)

Publication Number Publication Date
FI930984A true FI930984A (fi) 1993-03-05
FI930984A0 FI930984A0 (fi) 1993-03-05
FI113873B FI113873B (fi) 2004-06-30

Family

ID=10681827

Family Applications (2)

Application Number Title Priority Date Filing Date
FI930984A FI113873B (fi) 1990-09-07 1993-03-05 Menetelmä valmistaa muotoiltua ihmisen vasta-ainetta tai muotoiltua ihmisen vasta-ainefragmenttia, DNA-sekvenssejä, plasmidi ja pysyvä isäntäsolulinja
FI20011739A FI114611B (fi) 1990-09-07 2001-08-31 Muotoiltu ihmisen vasta-aine tai muotoiltu ihmisen vasta-ainefragmentti

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20011739A FI114611B (fi) 1990-09-07 2001-08-31 Muotoiltu ihmisen vasta-aine tai muotoiltu ihmisen vasta-ainefragmentti

Country Status (18)

Country Link
US (2) US6204366B1 (fi)
EP (1) EP0483961B1 (fi)
JP (2) JP3514456B2 (fi)
KR (1) KR930702526A (fi)
AT (1) ATE233279T1 (fi)
AU (1) AU653167B2 (fi)
BG (1) BG60716B1 (fi)
CA (1) CA2090961C (fi)
DE (1) DE69133200T2 (fi)
DK (1) DK0483961T3 (fi)
ES (1) ES2193129T3 (fi)
FI (2) FI113873B (fi)
GB (1) GB9019553D0 (fi)
HU (2) HUT67796A (fi)
NO (2) NO314595B1 (fi)
RO (1) RO113432B1 (fi)
UA (1) UA46691C2 (fi)
WO (1) WO1992004380A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5792852A (en) * 1992-11-16 1998-08-11 Cancer Research Fund Of Contra Costa Polynucleotides encoding modified antibodies with human milk fat globule specificity
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
CA2149529C (en) * 1992-11-16 2006-05-02 Fernado J. R. Do Couto Peptides and anti-sense peptides with broad neoplastic specificity
JPH07203974A (ja) * 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
EP0781847A1 (en) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanized monoclonal antibody
JP2001526021A (ja) * 1997-11-14 2001-12-18 ユーロ−セルティーク，エス．エイ． 合成の可変領域と改変された特異性を有する免疫グロブリン分子
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
AU2003239966B9 (en) * 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
US20040059093A1 (en) * 2002-07-16 2004-03-25 Stuart Bussell Methods to construct multimeric DNA and polymeric protein sequences as direct fusions or with linkers
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US20120093833A1 (en) * 2010-10-13 2012-04-19 Juan Carlos Almagro Human Oncostatin M Antibodies and Methods of Use
WO2012122514A1 (en) * 2011-03-09 2012-09-13 Centrose, Llc Extracellular targeted drug conjugates
RU2493165C1 (ru) * 2012-02-28 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок muc1, способ детекции белка muc1 с помощью наноантител
US11229701B2 (en) 2012-04-30 2022-01-25 Hibercell, Inc. Methods for identifying beta-glucan binding to immune cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3856072T2 (de) * 1987-01-07 1998-03-12 Imp Cancer Res Tech Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
ATE243754T1 (de) * 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
EP0401247A4 (en) * 1988-02-08 1991-01-23 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells
EP0442926A1 (en) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
EP0369816A3 (en) 1988-11-17 1990-09-12 The University Of Melbourne Monoclonal antibodies specific for human polymorphic epithelial mucin
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
DK0429242T3 (da) * 1989-11-17 1995-10-16 Unilever Plc Specifikke bindingsmidler

Also Published As

Publication number Publication date
US20020086978A1 (en) 2002-07-04
ES2193129T3 (es) 2003-11-01
ATE233279T1 (de) 2003-03-15
BG97607A (bg) 1994-03-31
NO314595B1 (no) 2003-04-14
RO113432B1 (ro) 1998-07-30
FI113873B (fi) 2004-06-30
DE69133200T2 (de) 2003-11-20
AU653167B2 (en) 1994-09-22
BG60716B1 (en) 1996-01-31
NO930825L (no) 1993-05-05
WO1992004380A1 (en) 1992-03-19
US6204366B1 (en) 2001-03-20
EP0483961A1 (en) 1992-05-06
DE69133200D1 (de) 2003-04-03
NO20014822D0 (no) 2001-10-04
EP0483961B1 (en) 2003-02-26
UA46691C2 (uk) 2002-06-17
NO315239B1 (no) 2003-08-04
JP3514456B2 (ja) 2004-03-31
CA2090961A1 (en) 1992-03-08
DK0483961T3 (da) 2003-06-23
FI114611B (fi) 2004-11-30
FI930984A0 (fi) 1993-03-05
AU8495391A (en) 1992-03-30
JPH06500468A (ja) 1994-01-20
NO20014822L (no) 1993-05-05
GB9019553D0 (en) 1990-10-24
JP2003061689A (ja) 2003-03-04
HUT67796A (en) 1995-04-28
HU9300609D0 (en) 1993-05-28
KR930702526A (ko) 1993-09-09
CA2090961C (en) 2004-01-20
NO930825D0 (no) 1993-03-05

Similar Documents

Publication Publication Date Title
FI930984A (fi) Specifika bindningsaemne
FI840219A (fi) Human-humanhybridom foer neoplasmer.
PT99934A (pt) Processo para a producao de um anticorpo anti-htnf alfa recombinante ou humanizado
DE3751585D1 (de) Hybridome, die monoklonale Antikörper gegen neue Mucin-Epitope produzieren.
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
FI922220A (fi) Specifika bindemedel.
EP0232871A3 (en) Human monoclonal antibody, hybridoma producing the same and its use
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
FR2455896A1 (fr) Vaccin contre l'enterotoxemie des lapins due au clostridium perfringens type e, et procede de fabrication de ce vaccin
RU93033872A (ru) Связывающие агенты, антитела, клетки плазмиды, применение плазмид, днк, вариабельные области антител, композиция, применение связующих агентов
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
DK1414859T3 (da) Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne

Legal Events

Date Code Title Description
MA Patent expired